Microparticle Assay for Universal Antibody Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting antigen-specific antibodies in animal species, especially wild or exotic species, are cumbersome due to the limited availability of species-specific secondary antibodies and antisera, requiring complex assays that often involve live pathogens.
Innovation Solution
A microparticle-based assay system that allows for direct labeling of biological samples, enabling the detection of antigen-specific antibodies without the need for species-specific conjugates, using biotinylated antibodies that bind to target antigen-bound microparticles, with detectable labels for fluorescence detection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional immunoassay methods are used for species without available secondary antibodies, then detection can be performed, but the assay complexity increases significantly and requires multiple species-specific reagents
Solution Approach 1:
The patent applies universality by making the microparticle itself species-agnostic. The microparticle is functionalized with antigen and a universal detection moiety (such as a fluorophore or enzyme), eliminating the need for species-specific secondary antibodies. This allows the same microparticle assay to detect antibodies from any species directly, converting a previously species-specific method into a universal platform that works across mammals, birds, reptiles, and other organisms.
Solution Approach 2:
The patent uses the microparticle as an intermediary that bridges the antigen and the detection system. Instead of using secondary antibodies as intermediaries (which require species matching), the microparticle serves as a direct carrier of both the antigen and the detection label, eliminating the need for species-specific bridging reagents and simplifying the assay architecture.
2Measurement precision
If conventional methods with species-specific secondary antibodies are used, then detection specificity is maintained, but the availability of reagents is limited for exotic species
Solution Approach 1:
The microparticle assay achieves universality by incorporating the detection label directly onto the microparticle surface alongside the antigen. This eliminates the requirement for secondary antibodies that would need to be raised against each species' antibody class, thereby expanding species availability while preserving detection specificity through the direct antigen-antibody-microparticle interaction.
Solution Approach 2:
The patent extracts the species-specific component (secondary antibody) from the assay system and replaces it with a universal microparticle construct. By removing the need for species-matched secondary reagents, the assay becomes applicable to exotic species where such reagents are unavailable, while maintaining specificity through the preserved antigen-antibody binding step.
3Reliability
If complex assays involving live pathogens are used for antibody detection, then detection capability is achieved, but safety risks and procedural complexity increase
Solution Approach 1:
The patent extracts only the essential immunogenic component (antigen) from the complete pathogen and uses it on the microparticle surface. This allows antibody detection without requiring live or inactivated whole pathogens, thereby eliminating safety risks associated with pathogen handling while preserving the ability to detect pathogen-specific antibodies through the retained antigenic determinants.
Solution Approach 2:
The patent converts the potential harm of using live pathogens into a benefit by isolating and using only the harmless antigen portion. The antigen retains its ability to elicit and bind specific antibodies but lacks the pathogenic properties of the complete organism, thus transforming a dangerous reagent into a safe one while maintaining detection capability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables rapid and universal detection of antigen-specific antibodies in various species, including those without available secondary antibodies, allowing for simultaneous detection of all antibody classes in unpurified samples, with high sensitivity and specificity, as demonstrated by the biotin-MIA assay.
Implementation Method 1
contacting target antigen-bound microparticles with the modified biological sample, wherein the target antigen bound-microparticles bind antigen-specific antibodies to form labeled microparticle complexes
Implementation Method 2
The technology involves the detection and analysis of a reaction (such as an antibody or other ligand) attached to microspheres or beads. The detecting instrument is a simplified flow cytometer, and lasers simultaneously identify the microsphere sets and measure the fluorescence associated with the reaction.
Data Source
AI summary
Disclosed herein is a rapid and universal assay for the detection of antigen-specific antibodies in biological samples. The assay allows for the detection of antigen-specific antibodies in any species, including species for which secondary antibodies or antisera have not been developed or are not available. Biological samples to be tested are directly labeled, such as with biotin, and contacted with antigen-bound microparticles. The presence of antigen-specific antibodies in the biological samples is detected using a binding partner for the label, such as a biotin binding partner, conjugated to a detectable label, such as a fluorophore. This improved test provides a total antibody assay that is capable of detecting all classes of antibodies simultaneously.